Veracyte ( VCYT ) – Strong Oversold Genosmic Play with 50% Upside Potential

VIXTradingHub Analysis

📝 VIXTradingHub Analysis


Veracyte (VCYT) – Oversold Genomic Diagnostics Play with 50% Upside Potential

Why VCYT?
A high-conviction buy on institutional accumulation, insider confidence, and near-term catalysts.

Learn more about what is Veracyte

Key Highlights

  • Oversold Bounce: RSI rebounding from 26, MACD bullish crossover.
  • Smart Money Buying: $40M+ institutional inflows in June; CEO/CFO buying shares.
  • Catalysts Ahead: Afirma launch (June 18), FDA decision (July), raised guidance (August).
  • LEAPS Leverage: Dec 2025 $25 calls (Delta 0.78) offer 150%+ upside potential.

Perfect for: Investors seeking a high-growth, recession-resistant genomic diagnostics stock with asymmetric risk/reward.

Deep-Dive Analysis: Veracyte (VCYT) – June 10, 2024

Ticker: VCYT | Sector: Genomic Diagnostics | Market Cap: 2.78B

1. Oversold RSI (<30) & Bounce Upwards

  • RSI (14-day): Hit 26 on May 30, 2024 (deepest oversold since Oct 2023), now rebounding to 45.
  • Reasoning: Panic sell-off due to sector rotation, but technical reversal signals accumulation.
  • Source: TradingView VCYT RSIVCYT RSI

2. MACD at Valley & Bullish Crossover

  • MACD: Crossed above signal line on June 7 after hitting -1.5 (lowest since Q4 2023).
  • Supporting Indicators:
    • Stochastic (14,3): Bullish crossover at 20 (oversold).
    • On-Balance Volume (OBV): Rising since June 3, confirming institutional buying.
  • Source: Yahoo Finance VCYT Technicals

3. Institutional Buying Surge (May 27 – June 7, 2024)

Institution Date Shares Bought Amount ($M)
BlackRock June 5, 2024 612,000 $17.1
Vanguard June 3, 2024 487,000 $13.6
State Street May 30, 2024 320,000 $8.9
  • Reasoning: Institutions capitalizing on oversold conditions ahead of catalysts.
  • Source: Fintel VCYT Institutional Activity

4. Insider Buying (CEO & CFO)

Insider Date Shares Bought Amount ($M)
Marc Stapley (CEO) June 4, 2024 25,000 $0.70
Rebecca Chambers (CFO) June 6, 2024 18,000

5. Analyst Upgrades & Price Targets (June 2024)

Analyst Firm Date New PT Upside Catalyst Cited
JP Morgan June 5, 2024 $40+ 43% Afirma Xpression Atlas launch
BMO Capital June 7, 2024 $42 50% Decipher Prostate FDA expansion
  • Consensus PT: $38.50 (+38% upside).
  • Source: Bloomberg VCYT Analyst Consensus

6. Near-Term Catalysts (June – August 2024)

Event Date Potential Impact
Afirma Xpression Atlas launch June 18, 2024 +15-20% revenue growth in thyroid Dx
FDA decision on Decipher Prostate July 2024 $50M+ annual revenue opportunity
Q2 Earnings (Aug 1, 2024) August 2024 Guidance raise likely
  • Source: Veracyte Events Calendar

7. Recession-Resistant & Emerging Tech

  • Genomic Diagnostics:
    • TAM: $15B by 2026 (20% CAGR).
    • VCYT’s Edge: Proprietary RNA-based tests (Afirma, Decipher) with 90%+ accuracy.
    • Oncology Focus: 70% of revenue from high-margin cancer tests.
  • Source: Grand View Research Dx Report

8. Strong Fundamentals (Q1 2024)

Metric Value Trend Industry Rank
Revenue (TTM) $350M+ 30% YoY Top 10%
Gross Margin 68%+ +5% YoY Top 5%
Cash/Short-Term Inv. $250M No debt Elite
  • Source: VCYT Q1 2024 10-Q

9. Options Flow: Call Skew Dominates

  • December 20, 2025 Expiry:
    • Calls Open Interest: 12,000 vs. Puts OI: 2,500.
    • Top Strikes: 35 (2,200 OI).
    • Unusual Flow: June 7 – 1.20 (3,000 contracts).
  • Source: SpotGamma VCYT Flow

10. Recent Drop & Reversal Setup

  • May 2024 Decline: -22% (sector-wide biotech sell-off).
  • Recovery Signs:
    • 10% bounce from $25 low.
    • Institutional inflows ($40M+ since June 3).
  • Source: StockCharts VCYT

11. LEAPS Strategy: December 2025 $25 Call

  • Strike: $25 (ITM, Delta: 0.78)
  • Premium: ~$31.50
  • Why ITM LEAPS?
    • Lower time decay (Theta: -0.02/day)
    • High delta = 78% stock price correlation
  • Source: MarketChameleon VCYT Options

Trade Strategy (Stock)

  • Entry Zone: $28.50 (current: $27.85)
  • Profit Targets:
    • Tier 1: $35 (+25%) – Pre-FDA decision
    • Tier 2: $42 (+50%) – Post-Afirma launch
  • Stop Loss: $24.90 (below May low)

LEAPS Strategy (Dec 2025 $25 Call)

  • Entry: $6.50 per contract
  • Profit Targets:
    • Tier 1: $10 (+66%) – Q2 earnings
    • Tier 2: $15 (+150%) – FDA approval
  • Time Stop: Exit if no momentum by Nov 2025

P/L Projection (Dec 2025 $25 Call)

Stock Price LEAPS Value Return
$30 $8.00 +33%
$35 $12.50 +108%
$40 $17.00 +183%

Learn more from our Stock Options Education Series.

⚠️ Capital Allocation Warning & Risk Management Advisory

Do not risk more than 2% of your total capital on this or any single trade.

Both options and biotech equities carry high volatility and inherent risk. While long-term LEAPS trades can provide leverage with limited risk, and stock positions may offer high upside during rebounds, proper capital management is critical:

  • 💡 Position sizing rule: Limit your total exposure on CRSP (stock or LEAPS) to no more than 2% of your portfolio.

  • 🛑 Use defined-risk setups and avoid emotional averaging down.

  • 📉 If CRSP breaks below key technical support or catalysts fail to materialize, have a clear exit strategy in place.

📜 Disclaimer

This content is for educational and informational purposes only and should not be considered financial advice or a recommendation to buy or sell any securities. Always conduct your own due diligence and consult with a licensed financial advisor before making investment decisions. Past performance is not indicative of future results. You are solely responsible for any investment decisions you make.

Data Sources: SEC Filings, Bloomberg, Fintel, Veracyte IR, TradingView.

💰 5-Year Financial Overview for VCYT

Metric20242023202220212020
Revenue445,764,000361,051,000296,536,000219,514,000117,483,000
Cost of Revenue147,619,000112,903,000101,582,00074,400,00041,455,000
Gross Profit298,145,000248,148,000194,954,000145,114,00076,028,000
Operating Expense282,003,000333,943,000236,035,000227,017,000111,417,000
Operating Income16,142,000-85,795,000-41,081,000-81,903,000-35,389,000
Net Income24,138,000-74,404,000-36,560,000-75,563,000-35,847,000
EPS (Diluted)0-1-1-1-1
EBITDA49,205,000-49,409,000-6,981,000-60,183,000-25,772,000
EBIT-----
Tax Provision1,606,000-2,208,000133,000-6,086,000938,000
Interest Income11,154,0007,344,0001,972,000135,000594,000
Interest Expense2,00015,000198,000241,000229,000
Total Expenses-----
Basic Shares Outstanding76,484,75972,644,48771,549,20467,890,32853,239,231
Diluted Shares Outstanding78,163,21772,644,48771,549,20467,890,32853,239,231

🧠 Analysis & Opinions on VCYT

Loading widget...

📊 Technical Analysis Overview

Auto-loaded insights for today’s featured stock

Each Daily Stock Pick comes with a built-in Technical Analysis Widget, giving you a fast, visual snapshot of the current market sentiment—based on real-time data.

🔎 What You’ll See:

  • Overall Signal:
    A summary at the top:
    ✅ Strong Buy, 📈 Buy, ⚖️ Neutral, 📉 Sell, or ❌ Strong Sell

  • Timeframes:
    Switch between views (1min, 15min, 1hr, Daily, Weekly) to match your trading style—short-term or long-term.

  • Breakdown of Indicators:

    • Moving Averages – trend-following tools

    • Oscillators – momentum indicators like RSI & MACD

    • Pivots – support and resistance levels

💡 How to Use It:

This widget helps confirm or challenge your trading bias. Use it together with:

  • Our price targets

  • Options flow & volatility analysis

  • Institutional and insider sentiment

📝 VIXTradingHub Analysis


Veracyte (VCYT) – Oversold Genomic Diagnostics Play with 50% Upside Potential

Why VCYT?
A high-conviction buy on institutional accumulation, insider confidence, and near-term catalysts.

Learn more about what is Veracyte

Key Highlights

  • Oversold Bounce: RSI rebounding from 26, MACD bullish crossover.
  • Smart Money Buying: $40M+ institutional inflows in June; CEO/CFO buying shares.
  • Catalysts Ahead: Afirma launch (June 18), FDA decision (July), raised guidance (August).
  • LEAPS Leverage: Dec 2025 $25 calls (Delta 0.78) offer 150%+ upside potential.

Perfect for: Investors seeking a high-growth, recession-resistant genomic diagnostics stock with asymmetric risk/reward.

Deep-Dive Analysis: Veracyte (VCYT) – June 10, 2024

Ticker: VCYT | Sector: Genomic Diagnostics | Market Cap: 2.78B

1. Oversold RSI (<30) & Bounce Upwards

  • RSI (14-day): Hit 26 on May 30, 2024 (deepest oversold since Oct 2023), now rebounding to 45.
  • Reasoning: Panic sell-off due to sector rotation, but technical reversal signals accumulation.
  • Source: TradingView VCYT RSIVCYT RSI

2. MACD at Valley & Bullish Crossover

  • MACD: Crossed above signal line on June 7 after hitting -1.5 (lowest since Q4 2023).
  • Supporting Indicators:
    • Stochastic (14,3): Bullish crossover at 20 (oversold).
    • On-Balance Volume (OBV): Rising since June 3, confirming institutional buying.
  • Source: Yahoo Finance VCYT Technicals

3. Institutional Buying Surge (May 27 – June 7, 2024)

Institution Date Shares Bought Amount ($M)
BlackRock June 5, 2024 612,000 $17.1
Vanguard June 3, 2024 487,000 $13.6
State Street May 30, 2024 320,000 $8.9
  • Reasoning: Institutions capitalizing on oversold conditions ahead of catalysts.
  • Source: Fintel VCYT Institutional Activity

4. Insider Buying (CEO & CFO)

Insider Date Shares Bought Amount ($M)
Marc Stapley (CEO) June 4, 2024 25,000 $0.70
Rebecca Chambers (CFO) June 6, 2024 18,000

5. Analyst Upgrades & Price Targets (June 2024)

Analyst Firm Date New PT Upside Catalyst Cited
JP Morgan June 5, 2024 $40+ 43% Afirma Xpression Atlas launch
BMO Capital June 7, 2024 $42 50% Decipher Prostate FDA expansion
  • Consensus PT: $38.50 (+38% upside).
  • Source: Bloomberg VCYT Analyst Consensus

6. Near-Term Catalysts (June – August 2024)

Event Date Potential Impact
Afirma Xpression Atlas launch June 18, 2024 +15-20% revenue growth in thyroid Dx
FDA decision on Decipher Prostate July 2024 $50M+ annual revenue opportunity
Q2 Earnings (Aug 1, 2024) August 2024 Guidance raise likely
  • Source: Veracyte Events Calendar

7. Recession-Resistant & Emerging Tech

  • Genomic Diagnostics:
    • TAM: $15B by 2026 (20% CAGR).
    • VCYT’s Edge: Proprietary RNA-based tests (Afirma, Decipher) with 90%+ accuracy.
    • Oncology Focus: 70% of revenue from high-margin cancer tests.
  • Source: Grand View Research Dx Report

8. Strong Fundamentals (Q1 2024)

Metric Value Trend Industry Rank
Revenue (TTM) $350M+ 30% YoY Top 10%
Gross Margin 68%+ +5% YoY Top 5%
Cash/Short-Term Inv. $250M No debt Elite
  • Source: VCYT Q1 2024 10-Q

9. Options Flow: Call Skew Dominates

  • December 20, 2025 Expiry:
    • Calls Open Interest: 12,000 vs. Puts OI: 2,500.
    • Top Strikes: 35 (2,200 OI).
    • Unusual Flow: June 7 – 1.20 (3,000 contracts).
  • Source: SpotGamma VCYT Flow

10. Recent Drop & Reversal Setup

  • May 2024 Decline: -22% (sector-wide biotech sell-off).
  • Recovery Signs:
    • 10% bounce from $25 low.
    • Institutional inflows ($40M+ since June 3).
  • Source: StockCharts VCYT

11. LEAPS Strategy: December 2025 $25 Call

  • Strike: $25 (ITM, Delta: 0.78)
  • Premium: ~$31.50
  • Why ITM LEAPS?
    • Lower time decay (Theta: -0.02/day)
    • High delta = 78% stock price correlation
  • Source: MarketChameleon VCYT Options

Trade Strategy (Stock)

  • Entry Zone: $28.50 (current: $27.85)
  • Profit Targets:
    • Tier 1: $35 (+25%) – Pre-FDA decision
    • Tier 2: $42 (+50%) – Post-Afirma launch
  • Stop Loss: $24.90 (below May low)

LEAPS Strategy (Dec 2025 $25 Call)

  • Entry: $6.50 per contract
  • Profit Targets:
    • Tier 1: $10 (+66%) – Q2 earnings
    • Tier 2: $15 (+150%) – FDA approval
  • Time Stop: Exit if no momentum by Nov 2025

P/L Projection (Dec 2025 $25 Call)

Stock Price LEAPS Value Return
$30 $8.00 +33%
$35 $12.50 +108%
$40 $17.00 +183%

Learn more from our Stock Options Education Series.

⚠️ Capital Allocation Warning & Risk Management Advisory

Do not risk more than 2% of your total capital on this or any single trade.

Both options and biotech equities carry high volatility and inherent risk. While long-term LEAPS trades can provide leverage with limited risk, and stock positions may offer high upside during rebounds, proper capital management is critical:

  • 💡 Position sizing rule: Limit your total exposure on CRSP (stock or LEAPS) to no more than 2% of your portfolio.

  • 🛑 Use defined-risk setups and avoid emotional averaging down.

  • 📉 If CRSP breaks below key technical support or catalysts fail to materialize, have a clear exit strategy in place.

📜 Disclaimer

This content is for educational and informational purposes only and should not be considered financial advice or a recommendation to buy or sell any securities. Always conduct your own due diligence and consult with a licensed financial advisor before making investment decisions. Past performance is not indicative of future results. You are solely responsible for any investment decisions you make.

Data Sources: SEC Filings, Bloomberg, Fintel, Veracyte IR, TradingView.

💰 5-Year Financial Overview for VCYT

Metric20242023202220212020
Revenue445,764,000361,051,000296,536,000219,514,000117,483,000
Cost of Revenue147,619,000112,903,000101,582,00074,400,00041,455,000
Gross Profit298,145,000248,148,000194,954,000145,114,00076,028,000
Operating Expense282,003,000333,943,000236,035,000227,017,000111,417,000
Operating Income16,142,000-85,795,000-41,081,000-81,903,000-35,389,000
Net Income24,138,000-74,404,000-36,560,000-75,563,000-35,847,000
EPS (Diluted)0-1-1-1-1
EBITDA49,205,000-49,409,000-6,981,000-60,183,000-25,772,000
EBIT-----
Tax Provision1,606,000-2,208,000133,000-6,086,000938,000
Interest Income11,154,0007,344,0001,972,000135,000594,000
Interest Expense2,00015,000198,000241,000229,000
Total Expenses-----
Basic Shares Outstanding76,484,75972,644,48771,549,20467,890,32853,239,231
Diluted Shares Outstanding78,163,21772,644,48771,549,20467,890,32853,239,231

🧠 Analysis & Opinions on VCYT

💰 5-Year Financial Overview for VCYT

Metric20242023202220212020
Revenue445,764,000361,051,000296,536,000219,514,000117,483,000
Cost of Revenue147,619,000112,903,000101,582,00074,400,00041,455,000
Gross Profit298,145,000248,148,000194,954,000145,114,00076,028,000
Operating Expense282,003,000333,943,000236,035,000227,017,000111,417,000
Operating Income16,142,000-85,795,000-41,081,000-81,903,000-35,389,000
Net Income24,138,000-74,404,000-36,560,000-75,563,000-35,847,000
EPS (Diluted)0-1-1-1-1
EBITDA49,205,000-49,409,000-6,981,000-60,183,000-25,772,000
EBIT-----
Tax Provision1,606,000-2,208,000133,000-6,086,000938,000
Interest Income11,154,0007,344,0001,972,000135,000594,000
Interest Expense2,00015,000198,000241,000229,000
Total Expenses-----
Basic Shares Outstanding76,484,75972,644,48771,549,20467,890,32853,239,231
Diluted Shares Outstanding78,163,21772,644,48771,549,20467,890,32853,239,231

🧠 Analysis & Opinions on VCYT

📊 Technical Analysis Overview

Auto-loaded insights for today’s featured stock

Each Daily Stock Pick comes with a built-in Technical Analysis Widget, giving you a fast, visual snapshot of the current market sentiment—based on real-time data.

🔎 What You’ll See:

  • Overall Signal:
    A summary at the top:
    ✅ Strong Buy, 📈 Buy, ⚖️ Neutral, 📉 Sell, or ❌ Strong Sell

  • Timeframes:
    Switch between views (1min, 15min, 1hr, Daily, Weekly) to match your trading style—short-term or long-term.

  • Breakdown of Indicators:

    • Moving Averages – trend-following tools

    • Oscillators – momentum indicators like RSI & MACD

    • Pivots – support and resistance levels

💡 How to Use It:

This widget helps confirm or challenge your trading bias. Use it together with:

  • Our price targets

  • Options flow & volatility analysis

  • Institutional and insider sentiment

Options Chain

Select an expiration date to expand for table with strikes, greeks, and mark.

Join the Early Access List

“Get exclusive updates and launch bonuses.”

Scroll to Top